ArticleTranslational oncology2018
Significance of Liquid Biopsy for Monitoring and Therapy Decision of Colorectal Cancer.
Article in Translational oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review.International journal of molecular sciences · 2018Pooled it
- Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer-results from the FIRE-4.5 study.Molecular oncology · 2025Trial
- FAM107A inhibits Invasion and migration of colorectal cancer by affecting EMT via the AKT pathway.Histology and histopathology · 2026Article
- Dynamics of RAS Mutations in Liquid Biopsies in Metastatic Colorectal Cancer Patients-Case Series and Literature Review.Journal of personalized medicine · 2024Review
- Liquid biopsy based HER2 amplification status in gastric cancer patients indicates clinical response.Heliyon · 2023Article
- Repeated Infusions of Brexucabtagene-autoleucel in Relapsed/Refractory Mantle Cell Lymphoma.HemaSphere · 2023Article
- Anti-epidermal growth factor receptor treatment for patients with NeoTherapeutic advances in medical oncology · 2023Article
- Molecular mechanism of colorectal cancer and screening of molecular markers based on bioinformatics analysis.Open life sciences · 2023Article
- Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care.Molecular oncology · 2022Article
- Recent advances in the diagnostic and therapeutic roles of microRNAs in colorectal cancer progression and metastasis.Frontiers in oncology · 2022Review
- Quantification of cell-free DNAfor the analysis of CD19-CAR-T cells during lymphoma treatment.Molecular therapy. Methods & clinical development · 2021Article
- Clinical Perspectives on Liquid Biopsy in Metastatic Colorectal Cancer.Frontiers in genetics · 2021Review
- Review
- Precision medicine for gastrointestinal cancer: Recent progress and future perspective.World journal of gastrointestinal oncology · 2020Review
- Tumor Profiling at the Service of Cancer Therapy.Frontiers in oncology · 2020Review
- Impact of Nutritional Indices on the Survival Outcomes of Patients with Colorectal Cancer.Cancer management and research · 2020Article
- Digital-Droplet PCR for Quantification of CD19-Directed CAR T-Cells.Frontiers in molecular biosciences · 2020Article
- Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer.Frontiers in oncology · 2020Article
- Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples.Scientific reports · 2019Article
- Advantage of Next-Generation Sequencing in Dynamic Monitoring of Circulating Tumor DNA over Droplet Digital PCR in Cetuximab Treated Colorectal Cancer Patients.Translational oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDespite therapeutic improvements, all patients with nonresectable metastatic colorectal cancer (mCRC) acquire resistance to treatment probably due to the growth of mutated clones. In contrast to tissue-based studies, liquid biopsies have enabled the opportunity to reveal emerging resistance to treatment by detecting mutated clones and noninvasively monitoring clonal dynamics during therapy.
methodsThe courses of three patients with mCRC who were initially RAS wild-type were monitored longitudinally using liquid biopsy with long-term follow-up of up to 20 sequential samples. Detection of fragmented RAS mutated circulating cell-free DNA (cf)DNA in plasma was performed by BEAMing. In addition, plasma digital droplet PCR was used to detect and quantify BRAF and PIK3CA mutated cfDNA. Changes of mutational load were correlated with imaging data.
resultsA combination of liquid biopsy and radiological imaging enabled visualization of the occurrence of clonal redistribution after discontinuation of anti-EGFR mAb therapy, as well as emerging RAS mutations during therapy with anti-EGFR mAb indicating resistance. Furthermore, we found that growth of RAS mutated clones is independent of direct selective pressure by anti-EGFR therapy, which is a significant and new finding of this study.
conclusionsOur findings demonstrated the whole spectrum of clonal selection and redistribution of mutated cell clones leading to acquired resistance. Given our observation that the growth of RAS mutated clones can evolve even in the absence of anti-EGFR mAb therapy, there is a clear imperative to monitor RAS mutations in serial blood draws in all RAS wild-type patients in general and independent of the therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.